1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base and Forecast Years Timeline
1.8. Key benefits for the stakeholders
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Research Process
3. EXECUTIVE SUMMARY
3.1. Key Findings
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. The Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
4.5. Analyst View
5. HORMONAL CONTRACEPTIVES MARKET BY PRODUCT TYPE
5.1. Introduction
5.2. Oral Contraceptives
5.3. Injectable Contraceptive
5.4. Skin Patches
5.5. Intrauterine Devices (IUDs)
5.6. Vaginal Rings
5.7. Emergency Contraceptive Pills
6. HORMONAL CONTRACEPTIVES MARKET BY HORMONE TYPE
6.1. Introduction
6.2. Progestin-Only Contraceptives
6.3. Combined Hormonal Contraceptives
7. HORMONAL CONTRACEPTIVES MARKET BY DISTRIBUTION CHANNEL
7.1. Introduction
7.2. Hospital
7.3. Retail
7.4. Online
8. HORMONAL CONTRACEPTIVES MARKET BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. By Product Type
8.2.2. By Hormone Type
8.2.3. By Distribution Channel
8.2.4. By Country
8.2.4.1. United States
8.2.4.2. Canada
8.2.4.3. Mexico
8.3. South America
8.3.1. By Product Type
8.3.2. By Hormone Type
8.3.3. By Distribution Channel
8.3.4. By Country
8.3.4.1. Brazil
8.3.4.2. Argentina
8.3.4.3. Others
8.4. Europe
8.4.1. By Product Type
8.4.2. By Hormone Type
8.4.3. By Distribution Channel
8.4.4. By Country
8.4.4.1. United Kingdom
8.4.4.2. France
8.4.4.3. Germany
8.4.4.4. Spain
8.4.4.5. Italy
8.4.4.6. Others
8.5. Middle East and Africa
8.5.1. By Product Type
8.5.2. By Hormone Type
8.5.3. By Distribution Channel
8.5.4. By Country
8.5.4.1. Saudi Arabia
8.5.4.2. UAE
8.5.4.3. Israel
8.5.4.4. Others
8.6. Asia Pacific
8.6.1. By Product Type
8.6.2. By Hormone Type
8.6.3. By Distribution Channel
8.6.4. By Country
8.6.4.1. Japan
8.6.4.2. China
8.6.4.3. India
8.6.4.4. South Korea
8.6.4.5. Indonesia
8.6.4.6. Thailand
8.6.4.7. Taiwan
8.6.4.8. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.1. Bayer AG
10.2. Pfizer, Inc.
10.3. Teva Pharmaceutical Industries Limited
10.4. Mylan N.V.
10.5. Johnson & Johnson
10.6. Merck & Co., Inc.
10.7. Church & Dwight, Co., Inc.
10.8. Ansell LTD.
10.9. Mayer Laboratories
10.10. The Female Health Company
10.11. Allergan plc
10.12. Afaxys, Inc.
10.13. Agile Therapeutics
10.14. Novartis AG
10.15. Prega International